구조모아 (StructureMoa)항암 chemical structure spider web
방문AstellasPfizer (Seagen)
분석
큐레이션 브리핑
경쟁 포지션: 1L standard of care in urothelial carcinoma with pembrolizumab.
기전. Binds Nectin-4 on urothelial tumor cells, internalizes, and releases MMAE after cathepsin B cleavage; microtubule disruption arrests mitosis and triggers apoptosis.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
Nectin-4
Locally advanced or metastatic urothelial carcinoma
US, EU, JP
Approved
padcev · enfortumab vedotin · Padcev · ASG-22ME · enfortumab-vedotin-ejfv
2026-09-10
Data Confidence · High
Development Signal · Established
Antibody-drug conjugate
MMAE (monomethyl auristatin E, tubulin inhibitor)
Protease-cleavable mc-vc-PAB, DAR ~3.8
Fully human anti-Nectin-4 IgG1
Nectin-4 is near-uniformly expressed in urothelial carcinoma, giving an unusually clean tumor-selective target in that tissue.
구조화 데이터
Nectin-4 is near-uniformly expressed in urothelial carcinoma, giving an unusually clean tumor-selective target in that tissue.
Nectin-4 loss, MMAE efflux, and tubulin alterations.
MMAE (monomethyl auristatin E, tubulin inhibitor)
Protease-cleavable mc-vc-PAB, DAR ~3.8
DAR 3.8
Nectin-4 · Nectin-4 expression is high in urothelial carcinoma; no companion diagnostic required.
Skin toxicity, hyperglycemia, peripheral neuropathy, and ocular surveillance
1L standard of care in urothelial carcinoma with pembrolizumab.
Advanced urothelial carcinoma, treatment-naive or platinum/IO-pretreated
1L with pembrolizumab; monotherapy in later lines
IV
1.25 mg/kg days 1, 8, 15 of a 28-day cycle (monotherapy)
ORR ~68% for EV + pembrolizumab in EV-302
Skin toxicity, hyperglycemia, peripheral neuropathy, and ocular surveillance
1L standard of care in urothelial carcinoma with pembrolizumab.
Binds Nectin-4 on urothelial tumor cells, internalizes, and releases MMAE after cathepsin B cleavage; microtubule disruption arrests mitosis and triggers apoptosis.
MMAE-induced immunogenic cell death is the proposed basis for synergy with PD-1 blockade.
Tubulin polymerization inhibition with bystander payload diffusion.
Nectin-4 expression is high in urothelial carcinoma; no companion diagnostic required.
Nectin-4 loss, MMAE efflux, and tubulin alterations.
구조화 데이터
xenograft model
Human, cynomolgus
ADC ~3.4 days; free MMAE ~2.4 days
ORR, PFS, OS; skin-toxicity onset as an exposure marker
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
구조화 데이터
ClinicalTrials.gov에 등록된 완료 예정일입니다. 추정이며 결과 발표를 단정하지 않습니다.
FDA accelerated approval (post-platinum/IO)
APPROVAL · 2019년 12월
FDA full approval on EV-301
APPROVAL · 2021년 7월
1L with pembrolizumab (EV-302)
APPROVAL · 2023년 12월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
AstellasPfizer (Seagen)
분석
큐레이션 브리핑
경쟁 포지션: 1L standard of care in urothelial carcinoma with pembrolizumab.
기전. Binds Nectin-4 on urothelial tumor cells, internalizes, and releases MMAE after cathepsin B cleavage; microtubule disruption arrests mitosis and triggers apoptosis.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
Nectin-4
Locally advanced or metastatic urothelial carcinoma
US, EU, JP
Approved
padcev · enfortumab vedotin · Padcev · ASG-22ME · enfortumab-vedotin-ejfv
2026-09-10
Data Confidence · High
Development Signal · Established
Antibody-drug conjugate
MMAE (monomethyl auristatin E, tubulin inhibitor)
Protease-cleavable mc-vc-PAB, DAR ~3.8
Fully human anti-Nectin-4 IgG1
Nectin-4 is near-uniformly expressed in urothelial carcinoma, giving an unusually clean tumor-selective target in that tissue.
구조화 데이터
Nectin-4 is near-uniformly expressed in urothelial carcinoma, giving an unusually clean tumor-selective target in that tissue.
Nectin-4 loss, MMAE efflux, and tubulin alterations.
MMAE (monomethyl auristatin E, tubulin inhibitor)
Protease-cleavable mc-vc-PAB, DAR ~3.8
DAR 3.8
Nectin-4 · Nectin-4 expression is high in urothelial carcinoma; no companion diagnostic required.
Skin toxicity, hyperglycemia, peripheral neuropathy, and ocular surveillance
1L standard of care in urothelial carcinoma with pembrolizumab.
Advanced urothelial carcinoma, treatment-naive or platinum/IO-pretreated
1L with pembrolizumab; monotherapy in later lines
IV
1.25 mg/kg days 1, 8, 15 of a 28-day cycle (monotherapy)
ORR ~68% for EV + pembrolizumab in EV-302
Skin toxicity, hyperglycemia, peripheral neuropathy, and ocular surveillance
1L standard of care in urothelial carcinoma with pembrolizumab.
Binds Nectin-4 on urothelial tumor cells, internalizes, and releases MMAE after cathepsin B cleavage; microtubule disruption arrests mitosis and triggers apoptosis.
MMAE-induced immunogenic cell death is the proposed basis for synergy with PD-1 blockade.
Tubulin polymerization inhibition with bystander payload diffusion.
Nectin-4 expression is high in urothelial carcinoma; no companion diagnostic required.
Nectin-4 loss, MMAE efflux, and tubulin alterations.
구조화 데이터
xenograft model
Human, cynomolgus
ADC ~3.4 days; free MMAE ~2.4 days
ORR, PFS, OS; skin-toxicity onset as an exposure marker
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
구조화 데이터
ClinicalTrials.gov에 등록된 완료 예정일입니다. 추정이며 결과 발표를 단정하지 않습니다.
FDA accelerated approval (post-platinum/IO)
APPROVAL · 2019년 12월
FDA full approval on EV-301
APPROVAL · 2021년 7월
1L with pembrolizumab (EV-302)
APPROVAL · 2023년 12월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.